Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- Announcement on Completion of Generic Drug Consistency Evaluation for Cefazolin Sodium for Injection
- Announcement on Subsidiary Obtaining Philippine Drug Registration Certificate for Pregabalin Capsules
- Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in Singapore
- Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan
- Announcement on Obtaining Approval for Production of Sitagliptin and Metformin Hydrochloride Sustained-release Tablets
Later from Shanghai Pharmaceuticals
- Announcement on Proposed Issuance of Debt Financing Products
- Announcement on Digoxin Tablets Passing Generic Drug Consistency Evaluation
- Announcement on Prednisolone Tablets Passing Generic Drug Consistency Evaluation
- Announcement on Progress in Proposed Public Listing and Transfer of 30% Equity in Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.
- Report for Q1 2026
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals